Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer

NCT07448493 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 230

Last updated 2026-03-04

No results posted yet for this study

Summary

GASTROBRAIN trial is an international (2 countries) observational, multicenter (15 centers) retrospective cohort study designed to investigate local treatment strategies for brain metastases of gastric and esophageal cancer

Conditions

Interventions

OTHER

Combined Local Treatment Modalities

Patients in this cohort received a combination of local treatment approaches. This includes: * NRS with postoperative WBRT; * NRS with postoperative SRT/SRS; * Preoperative SRS followed by NRS; * Combination radiotherapy (SRS and WBRT, SRT and WBRT, SRS and SRT)

PROCEDURE

Neurosurgical Resection (NRS): En-bloc (EBR), Total piecemeal (TPR), Subtotal (SPR) or Partial (PPR)

Patients in this cohort underwent neurosurgical resection as the primary local treatment for brain metastases. Surgical approaches include: * En-bloc resection (EBR): gross-total removal of the tumor as a single, intact specimen with no residual disease on postoperative MRI; * Total piecemeal resection (TPR): gross-total removal of the tumor in multiple fragments with no residual disease on postoperative MRI * Subtotal (SPR) or partial (PPR) piecemeal resection: incomplete removal of the tumor, with macroscopic residual disease on postoperative MRI. This includes: * Subtotal resection: 75-90% of tumor volume removed * Partial resection: 30-75% of tumor volume removed * Extent of resection unknown: surgical resection performed, but the precise extent could not be determined from available records

RADIATION

Radiotherapy (RT): Stereotactic Radiosurgery/Radiotherapy (SRS/SRT), Whole-Brain Radiotherapy (WBRT)

Patients in this cohort received radiotherapy as the primary local treatment modality for brain metastases. Treatment modalities include: * Stereotactic radiosurgery (SRS): single-fraction, high-precision radiation with a prescribed dose \> 12 Gy; * Staged stereotactic radiosurgery (stSRS): radiosurgery delivered in 2-3 stages, typically 2-4 weeks apart, allowing for tumor volume reduction between stages; * Stereotactic radiotherapy (hypofractionated) (SRT): stereotactic radiation delivered in multiple fractions, including: * 3 fractions (single dose 7-9 Gy, total dose 21-27 Gy); * 5 fractions (single dose 6-7 Gy, total dose 30-35 Gy); * 7 fractions (single dose 5 Gy, total dose 35 Gy). * Whole-brain radiotherapy (WBRT): conventional fractionated radiation to the entire brain.

OTHER

No Local Treatment

Patients in this cohort did not receive any local treatment for their brain metastases. This may include patients receiving best supportive care (BSC) (typically includes the administration of corticosteroids for symptomatic control of peritumoral edema and neurological symptoms) or systemic therapy alone. Reasons for not receiving local treatment may include poor performance status, extensive intracranial disease, or patient preference.

Sponsors & Collaborators

  • Blokhin's Russian Cancer Research Center

    lead OTHER

Principal Investigators

  • David Khalafyan, MD · Blokhin's Russian Cancer Research Center

  • Alexey Tryakin, MD, PhD, professor · Blokhin's Russian Cancer Research Center

  • Ali Bekyashev, MD, PhD, professor · Blokhin's Russian Cancer Research Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-01
Primary Completion
2027-10-01
Completion
2027-10-01

Countries

  • Belarus
  • Russia

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07448493 on ClinicalTrials.gov